Adocia SA (0QAI.L)
| Previous close | 6.12 |
| Open | 5.37 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 5.37 - 5.37 |
| 52-week range | 5.37 - 5.37 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 37.452M |
| Beta (5Y monthly) | 1.15 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -3.14 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
ADOCIA Announces its Annual Shareholders’ Meeting to Be Held on June 28, 2022 in Paris
LYON, France, May 20, 2022--Regulatory News: Adocia (Paris:ADOC) (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today that it will hold its annual shareholders’ meeting ("AGM") on June 28, 2022, at 10.00 am at Hotel de Talleyrand, in the offices of Jones Day, 2 rue Saint Florentin, 75001 Paris.
- Business Wire
ADOCIA Reports Financial Results of First Quarter 2022 and Provides Corporate Update
LYON, France, May 18, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, reports today its first quarter financial results for 2022 and provides corporate update.
- Business Wire
ADOCIA Announces The First Subject Treated In BioChaperone® Combo Clinical Studies with Partner Tonghua Dongbao
LYON, France, May 18, 2022--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the first subject treated in the BioChaperone® Combo ("BC Combo") CT046 clinical study.
